Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2318
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study ; volume:4 ; number:1 ; day:07 ; month:12 ; year:2004 ; pages:1-10 ; date:12.2004
BMC geriatrics ; 4, Heft 1 (07.12.2004), 1-10, 12.2004
- Urheber
-
Wohlreich, Madelaine M.
- Beteiligte Personen und Organisationen
-
Mallinckrodt, Craig H.
Watkin, John G.
Hay, Donald P.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2318-4-11
- URN
-
urn:nbn:de:1111-2016021817380
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wohlreich, Madelaine M.
- Mallinckrodt, Craig H.
- Watkin, John G.
- Hay, Donald P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Duloxetine in the treatment of major depressive disorder: an open-label study
Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial
Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder
Duloxetine in the treatment of major depressive disorder: an open-label study
Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial
Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder
Duloxetine in the treatment of major depressive disorder: an open-label study
Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies
Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial